Does Rallies show Form 4 insider transactions for ZVRA?

Yes. Rallies tracks ZVRA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ZVRA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ZVRA. It does not provide personalized investment advice.

ZVRA (Zevra Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Zevra Therapeutics, Inc. Common Stock (ZVRA) is a publicly traded Healthcare sector company. As of May 21, 2026, ZVRA trades at $10.22 with a market cap of $616.57M and a P/E ratio of 7.30. ZVRA moved +0.20% today. Year to date, ZVRA is +22.78%; over the trailing twelve months it is +18.93%. Its 52-week range spans $6.19 to $13.16. Analyst consensus is strong buy with an average price target of $24.00. Rallies surfaces ZVRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ZVRA stock inside the company?

Recent ZVRA insider activity includes Thompson Rahsaan sold 1.79K, McFarlane Neil F. sold 14.63K, Sangiovanni Timothy J. sold 3.00K, Schafer Joshua sold 10.50K, and McFarlane Neil F. sold 91.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ZVRA Key Metrics

Key financial metrics for ZVRA
Metric	Value
Price	$10.22
Market Cap	$616.57M
P/E Ratio	7.30
EPS	$1.40
Dividend Yield	0.00%
52-Week High	$13.16
52-Week Low	$6.19
Volume	40
Avg Volume	0
Revenue (TTM)	$106.47M
Net Income	$83.23M
Gross Margin	0.00%

Recent ZVRA Insider Trades

Thompson Rahsaan sold 1.79K (~$20.27K) on May 11, 2026.
McFarlane Neil F. sold 14.63K (~$125.19K) on Feb 9, 2026.
Sangiovanni Timothy J. sold 3.00K (~$27.55K) on Feb 3, 2026.
Schafer Joshua sold 10.50K (~$96.50K) on Feb 3, 2026.
McFarlane Neil F. sold 91.00K (~$853.43K) on Feb 2, 2026.

Latest ZVRA News

Zevra Q1 Revenue Soars 78% to $36.2M; Net Income Hits $37.9M — May 6, 2026
Zevra Therapeutics Records $106.5M Revenue, MIPLYFFA Sales of $87.4M in 2025 — Mar 12, 2026
Zevra Therapeutics Shares Rise 21.7% on Q4 Beat and GeneDx NPC Testing Pact — Mar 10, 2026
Zevra Posts $106.5M 2025 Revenue and $83.2M Net Income — Mar 9, 2026
Zevra Therapeutics Appoints CFO Justin Renz with 25+ Years Biopharma Finance Experience — Mar 5, 2026

ZVRA Analyst Consensus

7 analysts cover ZVRA: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.00.

Common questions about ZVRA

Who is trading ZVRA stock inside the company?: Recent ZVRA insider activity includes Thompson Rahsaan sold 1.79K, McFarlane Neil F. sold 14.63K, Sangiovanni Timothy J. sold 3.00K, Schafer Joshua sold 10.50K, and McFarlane Neil F. sold 91.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ZVRA?: Yes. Rallies tracks ZVRA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ZVRA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ZVRA. It does not provide personalized investment advice.